BACKGROUND: Vancomycin is an antibiotic of growing importance in the treatment of hospital infections, with particular emphasis on its value in the fight against methicillin-resistant Staphylococcus aureus. However its usage profile must be evaluated to assure maximum benefit and minimum risk. FINDINGS: A cross-sectional retrospective study was carried out among inpatients that received vancomycin in a Brazilian quaternary hospital. The occurrence of adverse reactions reported was evaluated in medical records relating to patients taking vancomycin during a one year period. Males comprised 52% (95% CI: 41.7-60.2%) of the sample population, with a mean age of 50.6 (95% CI: 47.2-54.0) years and mean treatment period of 9.7 (95% CI: 8.0-11.5) Days. It was verified that nephrotoxicity occurred in 18.4% (95% CI: 11.3-27.5) of patients, Red man syndrome occurred in 2% (95% CI 0.2-7.2), while the occurrence of thrombocytopenia was 7.1% (95% CI: 2.9-14.2). CONCLUSIONS: It may be noted that even after 50 years of use, adverse reactions associated with vancomycin continue with high frequency, presenting a public health problem, especially considering its current use in cases of multidrug resistant infections. In this context, we emphasize the importance of intensive pharmacovigilance in hospital as a surveillance tool after drug approval by the sanitary authority.
BACKGROUND:Vancomycin is an antibiotic of growing importance in the treatment of hospital infections, with particular emphasis on its value in the fight against methicillin-resistant Staphylococcus aureus. However its usage profile must be evaluated to assure maximum benefit and minimum risk. FINDINGS: A cross-sectional retrospective study was carried out among inpatients that received vancomycin in a Brazilian quaternary hospital. The occurrence of adverse reactions reported was evaluated in medical records relating to patients taking vancomycin during a one year period. Males comprised 52% (95% CI: 41.7-60.2%) of the sample population, with a mean age of 50.6 (95% CI: 47.2-54.0) years and mean treatment period of 9.7 (95% CI: 8.0-11.5) Days. It was verified that nephrotoxicity occurred in 18.4% (95% CI: 11.3-27.5) of patients, Red man syndrome occurred in 2% (95% CI 0.2-7.2), while the occurrence of thrombocytopenia was 7.1% (95% CI: 2.9-14.2). CONCLUSIONS: It may be noted that even after 50 years of use, adverse reactions associated with vancomycin continue with high frequency, presenting a public health problem, especially considering its current use in cases of multidrug resistant infections. In this context, we emphasize the importance of intensive pharmacovigilance in hospital as a surveillance tool after drug approval by the sanitary authority.
Authors: C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt Journal: Clin Pharmacol Ther Date: 1981-08 Impact factor: 6.875
Authors: Annette Von Drygalski; Brian R Curtis; Daniel W Bougie; Janice G McFarland; Scott Ahl; Indra Limbu; Kelty R Baker; Richard H Aster Journal: N Engl J Med Date: 2007-03-01 Impact factor: 91.245
Authors: K Vance-Bryan; J C Rotschafer; S S Gilliland; K A Rodvold; C M Fitzgerald; D R Guay Journal: J Antimicrob Chemother Date: 1994-04 Impact factor: 5.790
Authors: Mehdi Mohammadi; Zahra Jahangard-Rafsanjani; Amir Sarayani; Molouk Hadjibabaei; Maryam Taghizadeh-Ghehi Journal: Drug Saf Date: 2017-01 Impact factor: 5.606
Authors: Adam M Bressler; Ali A Hassoun; Louis D Saravolatz; Valerie Ravenna; Chris N Barnes; Bibiana Castaneda-Ruiz Journal: Drugs Real World Outcomes Date: 2019-12
Authors: Nitin B Mali; Siddharth P Deshpande; Poorwa P Wandalkar; Vishal A Gupta; Niteen D Karnik; Nithya J Gogtay; Gita Nataraj; Preeti R Mehta; Urmila Thatte Journal: Indian J Crit Care Med Date: 2019-11
Authors: Nitin B Mali; Milind S Tullu; Poorwa P Wandalkar; Siddharth P Deshpande; Vinod C Ingale; Chandrahas T Deshmukh; Nithya J Gogtay; Urmila M Thatte Journal: Indian J Crit Care Med Date: 2019-11